AllianceBernstein’s Karyopharm Therapeutics KPTI Stock Holding History

AllianceBernstein’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12,854	Closed	-$291K	–	3269
2024 Q1	$291K	Hold	12,854	–	–	﹤0.01%	2807
2023 Q4	$167K	Hold	12,854	–	–	﹤0.01%	3009
2023 Q3	$258K	Sell	12,854 -2,775	-18%	-$62.3K	﹤0.01%	2872
2023 Q2	$420K	Buy	15,629 +3,774	+32%	+$163K	﹤0.01%	2731
2023 Q1	$692K	Buy	11,855 +1,320	+13%	+$65.2K	﹤0.01%	2402
2022 Q4	$537K	Buy	10,535 +1,326	+14%	+$91.9K	﹤0.01%	2593
2022 Q3	$754K	Buy	9,209 +1,340	+17%	+$100K	﹤0.01%	2441
2022 Q2	$532K	Buy	7,869 +134	+2%	+$12.3K	﹤0.01%	2657
2022 Q1	$855K	Buy	7,735 +13	+0.2%	+$1.62K	﹤0.01%	2482
2021 Q4	$745K	Hold	7,722	–	–	﹤0.01%	2571
2021 Q3	$674K	Hold	7,722	–	–	﹤0.01%	2644
2021 Q2	$1.2M	Sell	7,722 -927	-11%	-$135K	﹤0.01%	2456
2021 Q1	$1.36M	Hold	8,649	–	–	﹤0.01%	2284
2020 Q4	$2.01M	Hold	8,649	–	–	﹤0.01%	1982
2020 Q3	$1.89M	Sell	8,649 -133	-2%	-$32.5K	﹤0.01%	1878
2020 Q2	$2.5M	Buy	8,782 +2,807	+47%	+$830K	﹤0.01%	1721
2020 Q1	$1.72M	Hold	5,975	–	–	﹤0.01%	1753
2019 Q4	$1.72M	Buy	5,975 +80	+1%	+$17.4K	﹤0.01%	2047
2019 Q3	$851K	Sell	5,895 -2,047	-26%	-$278K	﹤0.01%	2320
2019 Q2	$714K	Buy	7,942 +1,907	+32%	+$153K	﹤0.01%	2459
2019 Q1	$529K	Buy	6,035 +1,760	+41%	+$195K	﹤0.01%	2500
2018 Q4	$601K	Buy	4,275 +146	+4%	+$24.6K	﹤0.01%	2402
2018 Q3	$1.05M	Hold	4,129	–	–	﹤0.01%	2306
2018 Q2	$1.05M	Sell	4,129 -713	-15%	-$176K	﹤0.01%	2292
2018 Q1	$975K	Sell	4,842 -3,053	-39%	-$609K	﹤0.01%	2268
2017 Q4	$1.14M	Buy	7,895 +5,000	+173%	+$803K	﹤0.01%	2188
2017 Q3	$477K	Hold	2,895	–	–	﹤0.01%	2589
2017 Q2	$393K	Buy	2,895 +700	+32%	+$104K	﹤0.01%	2700
2017 Q1	$423K	Sell	2,195 -134	-6%	-$21.5K	﹤0.01%	2586
2016 Q4	$328K	Hold	2,329	–	–	﹤0.01%	2705
2016 Q3	$340K	Hold	2,329	–	–	﹤0.01%	2664
2016 Q2	$234K	Buy	2,329 +454	+24%	+$59K	﹤0.01%	2766
2016 Q1	$251K	Sell	1,875 -274	-13%	-$30.2K	﹤0.01%	2647
2015 Q4	$427K	Sell	2,149 -319	-13%	-$69.1K	﹤0.01%	2507
2015 Q3	$390K	Sell	2,468 -36,437	-94%	-$9.74M	﹤0.01%	2575
2015 Q2	$15.9M	Buy	38,905 +11,622	+43%	+$5.02M	0.01%	794
2015 Q1	$12.5M	Sell	27,283 -629	-2%	-$271K	0.01%	856
2014 Q4	$15.7M	Sell	27,912 -3,564	-11%	-$2.02M	0.01%	773
2014 Q3	$16.5M	Buy	31,476 +3,977	+14%	+$2.24M	0.01%	740
2014 Q2	$19.2M	Sell	27,499 -2,262	-8%	-$1.05M	0.02%	708
2014 Q1	$13.8M	Sell	29,761 -534	-2%	-$271K	0.01%	763
2013 Q4	$10.4M	Buy	+30,295	New	+$8.37M	0.01%	843

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's KPTI Position: Q2 2024 in Review

AllianceBernstein sold out of Karyopharm Therapeutics (KPTI) in Q2 2024, closing a stake of 12,854 shares — an estimated $291K sold.

AllianceBernstein first reported a position in KPTI in Q4 2013 and held it in 42 quarters. The position peaked at $19.2M in Q2 2014. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.

AllianceBernstein reported no remaining Karyopharm Therapeutics position as of Q2 2024 after selling out during the quarter.
AllianceBernstein sold 12,854 Karyopharm Therapeutics shares in Q2 2024, an estimated $291K.
AllianceBernstein first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 42 quarters.
AllianceBernstein's Karyopharm Therapeutics position peaked at $19.2M in Q2 2014.
114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.

Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.